Event Date/Time: May 24, 2011 | End Date/Time: May 26, 2011 |
Description
Several productivity bottlenecks need to be overcome in order to optimize the efficiency of antibody processing.
Following 2010’s successful meeting, Hanson Wade is again hosting the World Antibody Manufacturing & Development Summit to bring together thought leaders to drive antibody development forward.
• Get the latest market intelligence on the biosimilar landscape. Hear what next generation technologies can keep you ahead of the game
• Discover how to manage the lifecycle of a QbD product
• Be updated on the post-approval lifecycle management (PALM) plan that is being developed for antibody products undergoing licensing with QbD
• Refine your strategy for rapid transfer of protein therapeutics into existing manufacturing facilities
• See case studies of creative solutions to downstream capacity to maximise high cell culture productivity
• Learn about the best ways to approach the regulators and how QbD approaches can be included in regulatory submissions
• Acquire the key design tips for enhancing CMC probability of success
• Get advice on how to implement single-use processing across all unit operations
• Hear the latest case studies on antibody formulations, including stability comparability approaches, changing drug substance container, and the implications of moving to higher titers
• Get an insight into the latest techniques for high-throughput screening of chromatography resins
Designed entirely by industry, we’ve worked with thought leaders from Novartis, Merck & Co, Johnson & Johnson, Pfizer, MedImmune, Genentech, Abbott, Bayer, UCB, Amgen and more to produce a focussed program that tackles the challenges most relevant to you.
Your expert speaker panel includes:
• Victor Vinci, Director, Purification Development & Viral Safety, Eli Lilly
• Ron Taticek, Senior Director & Head, Genentech
• Michael Buckley, Vice President, Process Sciences, Takeda
• Kaia Agarwal, Vice President, Regulatory Affairs, Genzyme
• Mark Davis, Development Scientist, EMD Serono
• Paul Jorjorian, Engineer, Bristol-Myers Squibb
• Mayo Pujols, Director, MedImmune
• Stephen Lu, Senior Scientist, Abbott
• Brent Schreiber, Senior Engineer, Bristol-Myers Squibb
• Norbert Schuelke, Associate Director, Biologics Process Development, Millennium
• Mark Byers, Associate Director, Manufacturing Sciences, Biogen Idec
• Paul Hanson, Staff Engineer II, Millennium
• David Pollard, Associate Director, Bioprocess R&D, Merck & Co
• Hemant Joshi, Scientist IV, Process Development, Boehringer Ingelheim
• Jason Kantor, Research Analyst, RBC Capital Markets
• Kevin Maloney, Associate Director, protein Pharmaceutical Development, Biogen Idec
For more information about the agenda or what you can expect to learn please contact me at info@hansonwade.com
Katie McQue, Program Director